Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Distribution of patients according to radiopathologic categories and refractoriness to medication
Pathologic Features Medication P Value
Response (n) Refractoriness (n)
Neoplastic lesion 8 5 .19
Malformations of cortical development 0 10 .001^a
Vascular lesions 7 2 .03
Atrophy/gliosis from acquired insults 4 4 .71
Other 1 3 .49
Normal 1 3 .62
Total 21 27 .004^b
↵a Statistical significance threshold after Bonferroni method, P = .008.
↵b P value obtained by Fisher exact test on the overall 2 × 6 contingency table (statistical significance threshold P = .05).

Pathologic Features	Medication		P Value
Pathologic Features	Response (n)	Refractoriness (n)	P Value
Neoplastic lesion	8	5	.19
Malformations of cortical development	0	10	.001^a
Vascular lesions	7	2	.03
Atrophy/gliosis from acquired insults	4	4	.71
Other	1	3	.49
Normal	1	3	.62
Total	21	27	.004^b